Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

By WebmasterJune 29, 2021November 1st, 2024No Comments

Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

Previous PostRenovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors
Next PostVenatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection